All In Biotech

Drug Trial Radar · NCT02045277

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

Feb 2014

Primary completion

Nov 2014

Study completion Nov 2014

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
Collaborators
Dow Pharmaceutical Sciences
First posted
Jan 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and efficacy of a topical lotion

Conditions

  • Plaque Psoriasis

Interventions

  • IDP-118 LotionDrug

    Lotion

  • IDP-118 Monad HP LotionDrug

    Active Comparator

  • IDP-118 Monad Taz LotionDrug

    Active Comparator

  • IDP-118 Vehicle LotionDrug

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 8Time frame: 8 weeks
  2. Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Weeks 2, 4, 6, and 12Time frame: Weeks 2, 4, 6, and 12 (4-week follow-up)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Valeant Site 13

    Encino, California

  • Valeant Site 11

    San Diego, California

  • Valeant Site 15

    Santa Rosa, California

  • Valeant Site 10

    Augusta, Georgia

  • Valeant Site 09

    Newnan, Georgia

  • Valeant Site 08

    Louisville, Kentucky

  • Valeant Site 04

    Rockville, Maryland

  • Valeant Site 14

    Clinton Township, Michigan

  • Valeant Site 07

    Fridley, Minnesota

  • Valeant Site 01

    East Windsor, New Jersey

  • Valeant Site 03

    New York, New York

  • Valeant Site 17

    Rochester, New York

  • Valeant Site 02

    High Point, North Carolina

  • Valeant Site 05

    Austin, Texas

  • Valeant Site 06

    College Station, Texas

  • Valeant Site 16

    Salt Lake City, Utah

  • Valeant Site 18

    Lynchburg, Virginia

  • Valeant Site 12

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.